List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3947196/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 165-173.	3.9	4
2	Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1564-1571.	2.5	3
3	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clinical Cancer Research, 2021, 27, 320-329.	7.0	46
4	Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCHÂdatabase. Cancer Causes and Control, 2021, 32, 189-197.	1.8	1
5	Safety of concomitant therapy with radiumâ€223 and abiraterone or enzalutamide in a realâ€world population. Prostate, 2021, 81, 390-397.	2.3	5
6	Association between PEG3 DNA methylation and high-grade cervical intraepithelial neoplasia. Infectious Agents and Cancer, 2021, 16, 42.	2.6	3
7	Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer and Prostatic Diseases, 2020, 23, 419-428.	3.9	22
8	Asian Race and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2165-2170.	2.5	6
9	Obesity, race, and longâ€ŧerm prostate cancer outcomes. Cancer, 2020, 126, 3733-3741.	4.1	32
10	Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. Anticancer Research, 2020, 40, 1459-1462.	1.1	11
11	Racial Discrepancies in Overall Survival among Men Treated with ²²³ Radium. Journal of Urology, 2020, 203, 331-337.	0.4	25
12	Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. Cancer Epidemiology, 2019, 62, 101578.	1.9	14
13	Dietary inflammatory index (DII) and risk of prostate cancer in a case–control study among Black and White US Veteran men. Prostate Cancer and Prostatic Diseases, 2019, 22, 580-587.	3.9	14
14	Does race predict the development of metastases in men who receive androgenâ€deprivation therapy for a biochemical recurrence after radical prostatectomy?. Cancer, 2019, 125, 434-441.	4.1	3
15	DNA methylation of imprinted gene control regions in the regression of lowâ€grade cervical lesions. International Journal of Cancer, 2018, 143, 552-560.	5.1	9
16	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 783-789.	2.5	1
17	Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes and Control, 2018, 29, 581-588.	1.8	30
18	Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2018, 21, 252-259.	3.9	71

#	Article	IF	CITATIONS
19	Obese patients with castrationâ€resistant prostate cancer may be at a lower risk of allâ€cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2018, 122, 76-82.	2.5	15
20	Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining. Frontiers in Immunology, 2018, 9, 2925.	4.8	32
21	PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2018, 21, 238-244.	3.9	12
22	Re: Commentary on "The association between sexual function and prostate cancer risk in US veterans". Asian Journal of Andrology, 2018, 20, 100.	1.6	0
23	Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. International Journal of Urology, 2017, 24, 151-156.	1.0	8
24	Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. Scientific Reports, 2017, 7, 43551.	3.3	10
25	Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. Journal of Urology, 2017, 198, 650-656.	0.4	3
26	Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer Prevention Research, 2017, 10, 319-326.	1.5	23
27	Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer, 2017, 123, 4199-4206.	4.1	30
28	Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping. European Urology, 2017, 72, 78-83.	1.9	27
29	Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget, 2017, 8, 71393-71399.	1.8	10
30	Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk. Oncotarget, 2017, 8, 94900-94909.	1.8	29
31	Do all men with pathological Gleason score 8–10 prostate cancer have poor outcomes? Results from the <scp>SEARCH</scp> database. BJU International, 2016, 118, 250-257.	2.5	12
32	Adverse pathology and undetectable ultrasensitive prostateâ€specific antigen after radical prostatectomy: is adjuvant radiation warranted?. BJU International, 2016, 117, 897-903.	2.5	7
33	The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. Journal of Urology, 2016, 196, 715-720.	0.4	11
34	Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. European Urology, 2016, 69, 885-891.	1.9	26
35	Effect of Body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. Scientific Reports, 2016, 6, 19034.	3.3	5
36	Metabolic syndromeâ€like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (<scp>REDUCE</scp>) study. BJU International, 2015, 115, 736-743.	2.5	35

#	Article	IF	CITATIONS
37	Development and external validation of a prostate health index-based nomogram for predicting prostate cancer. Scientific Reports, 2015, 5, 15341.	3.3	15
38	Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study. Journal of Urology, 2015, 194, 52-57.	0.4	3
39	Carbohydrate intake, glycemic index and prostate cancer risk. Prostate, 2015, 75, 430-439.	2.3	15
40	IL-10, IL-15, IL-17, and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV16/18 genotypes. Infectious Agents and Cancer, 2015, 10, 10.	2.6	15
41	The Association of Exercise with Both Erectile and Sexual Function in Black and White Men. Journal of Sexual Medicine, 2015, 12, 1202-1210.	0.6	20
42	Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study. Clinical Cancer Research, 2015, 21, 756-762.	7.0	91
43	Vasectomy: potential links to an increased risk of aggressive prostate cancer?. Expert Review of Anticancer Therapy, 2015, 15, 1123-1125.	2.4	3
44	Maternal cadmium, iron and zinc levels, DNA methylation and birth weight. BMC Pharmacology & Toxicology, 2015, 16, 20.	2.4	95
45	Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Prevention Research, 2015, 8, 1055-1060.	1.5	28
46	Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study. Clinical Cancer Research, 2014, 20, 5331-5338.	7.0	26
47	Genetic Variants in Predicting Aggressive Prostate Cancer: "Ready for Prime Time?― European Urology, 2014, 65, 1076-1077.	1.9	1
48	Erythrocyte folate concentrations, CpG methylation at genomically imprinted domains, and birth weight in a multiethnic newborn cohort. Epigenetics, 2014, 9, 1120-1130.	2.7	73
49	Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2936-2942.	2.5	84
50	The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort. Cancer Causes and Control, 2014, 25, 1029-1035.	1.8	31
51	HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes and Control, 2014, 25, 1055-1062.	1.8	62
52	Can We Eat Our Way to a Lower Prostate Cancer Risk, and If So, How?. European Urology, 2014, 65, 895-896.	1.9	0
53	Maternal Stress, Preterm Birth, and DNA Methylation at Imprint Regulatory Sequences in Humans. Genetics & Epigenetics, 2014, 6, GEG.S18067.	2.5	93
54	Maternal BMI, IGF-I Levels, and Birth Weight in African American and White Infants. International Journal of Pediatrics (United Kingdom), 2013, 2013, 1-7.	0.8	27

#	Article	IF	CITATIONS
55	Associations between Methylation of Paternally Expressed Gene 3 (PEG3), Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. PLoS ONE, 2013, 8, e56325.	2.5	73
56	Associations between birth and one year anthropometric measurements and IGF2 and IGF2R genetic variants in African American and Caucasian American infants. Journal of Pediatric Genetics, 2013, 2, .	0.7	1
57	Associations between Intake of Folate, Methionine, and Vitamins B-12, B-6 and Prostate Cancer Risk in American Veterans. Journal of Cancer Epidemiology, 2012, 2012, 1-9.	1.1	17
58	Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer, 2012, 12, 389.	2.6	20
59	Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women. Infectious Agents and Cancer, 2011, 6, 20.	2.6	33
60	Natural Killer Cell-Endothelial Cell Interactions in Xenotransplantation. Immunologic Research, 2000, 22, 165-176.	2.9	27
61	Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice, 0, , .	0.5	0